Share Price and Basic Stock Data
Last Updated: December 9, 2025, 5:55 pm
| PEG Ratio | -17.65 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aashka Hospitals Ltd operates in the Hospitals & Medical Services sector, a space marked by high demand yet equally high operational costs. The company reported a market capitalization of ₹214 Cr, with its stock currently priced at ₹91.2. Over recent years, revenue trends have shown volatility. For instance, sales peaked at ₹40.69 Cr in FY 2021 but plummeted to ₹18.94 Cr in FY 2023. This decline reflects the challenges faced during the pandemic and its aftermath, which saw significant fluctuations in patient inflow and operational capabilities. However, a slight recovery is evident with reported sales of ₹22.87 Cr in FY 2024. The latest quarterly figures show a modest increase, with sales reaching ₹12.07 Cr in March 2024, indicating a potential stabilization in revenue. Still, the overall trajectory raises questions about the sustainability of growth in a sector that often requires heavy capital investment and operational efficiency.
Profitability and Efficiency Metrics
Profitability metrics for Aashka Hospitals reveal a challenging landscape. The company recorded a net profit of only ₹3.27 Cr in FY 2025, translating to a high Price-to-Earnings (P/E) ratio of 187, indicating that investor expectations may be inflated relative to actual earnings. The operating profit margin (OPM) has been notably erratic, swinging from a high of 31.7% in September 2021 to a troubling -6.75% in March 2023, before recovering to 30.07% in March 2024. This volatility in margins underscores the operational challenges the company faces, particularly in managing costs effectively. The Return on Equity (ROE) is relatively low at 2.39%, signaling that the company is not generating substantial returns for its shareholders. Efficiency ratios further illustrate a mixed picture; the Cash Conversion Cycle (CCC) stands at just 4.23 days, indicating that the company manages its working capital effectively, but the overall profitability metrics suggest that revenue generation remains a pressing concern.
Balance Sheet Strength and Financial Ratios
The balance sheet of Aashka Hospitals reflects a cautious approach to leverage, with total borrowings reported at ₹12.61 Cr against reserves of ₹76.17 Cr. This conservative borrowing strategy results in a Debt-to-Equity ratio of 0.12, which appears comfortable, especially in a capital-intensive industry like healthcare. The Interest Coverage Ratio (ICR) stands at a healthy 4.41x, indicating that the company can comfortably meet its interest obligations. However, the low Return on Capital Employed (ROCE) of 4.07% raises concerns about the effectiveness of capital utilization. Additionally, the book value per share has shown a progressive increase to ₹42.60 in March 2024, which could provide some cushion against market volatility. Yet, the overall financial ratios suggest that while the company has managed its liabilities prudently, it needs to enhance its operational efficiency and revenue generation to bolster shareholder value.
Shareholding Pattern and Investor Confidence
Aashka Hospitals displays a stable shareholding structure, with promoters holding 61.34% of the equity as of March 2025. This level of promoter holding can instill confidence among retail investors, as it indicates a strong commitment from the founding members. The public shareholding stands at 38.68%, which, while lower than the promoter stake, reflects a reasonable level of interest from retail investors, evidenced by a shareholder base of 1,172. However, the decline in the number of shareholders from 3,245 in March 2022 to the current figure suggests a potential waning interest, which could be a red flag. Moreover, the absence of Foreign Institutional Investors (FIIs) or Domestic Institutional Investors (DIIs) could imply a lack of broader institutional confidence in the stock at this juncture, potentially limiting liquidity and further investment in the company.
Outlook, Risks, and Final Insight
Looking ahead, Aashka Hospitals faces a dual-edged sword of opportunity and risk. On one hand, the gradual recovery in revenue and improvements in operating profit margins suggest a potential turnaround, particularly if the company can maintain operational efficiencies and control costs. On the other hand, the high P/E ratio signals that the stock may be overvalued if profitability does not improve significantly. Risks are also present in the form of fluctuating patient volumes and the ongoing challenges posed by regulatory changes and competition in the healthcare sector. Investors should remain vigilant about the company’s ability to sustain its recovery trajectory. In a sector where margins can be thin and operational challenges abound, Aashka Hospitals must not only stabilize its revenue but also ensure that it converts that revenue into meaningful profits to attract and retain investor interest.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aashka Hospitals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 41.9 Cr. | 125 | 195/120 | 8.54 | 117 | 2.80 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 19.1 Cr. | 18.2 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.0 Cr. | 9.70 | 20.9/9.40 | 111 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 113 Cr. | 60.5 | 98.7/55.2 | 25.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.6 Cr. | 3.82 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,211.36 Cr | 755.87 | 93.12 | 99.39 | 0.35% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.82 | 28.42 | 11.32 | 11.54 | 7.41 | 10.80 | 12.07 | 12.36 | 10.28 |
| Expenses | 19.41 | 19.41 | 12.06 | 10.80 | 7.91 | 9.97 | 8.44 | 7.89 | 10.49 |
| Operating Profit | 5.41 | 9.01 | -0.74 | 0.74 | -0.50 | 0.83 | 3.63 | 4.47 | -0.21 |
| OPM % | 21.80% | 31.70% | -6.54% | 6.41% | -6.75% | 7.69% | 30.07% | 36.17% | -2.04% |
| Other Income | 0.04 | 0.04 | 0.09 | 0.06 | 3.06 | 2.61 | 1.61 | 0.07 | 4.20 |
| Interest | 1.43 | 1.43 | 1.23 | -0.17 | 3.17 | 1.46 | 1.45 | 1.02 | 0.70 |
| Depreciation | 1.45 | 1.45 | 1.44 | 1.44 | 1.49 | 1.47 | 1.45 | 1.58 | 1.37 |
| Profit before tax | 2.57 | 6.17 | -3.32 | -0.47 | -2.10 | 0.51 | 2.34 | 1.94 | 1.92 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 17.65% | 17.09% | 16.49% | 14.58% |
| Net Profit | 2.57 | 6.17 | -3.33 | -0.47 | -2.10 | 0.42 | 1.93 | 1.62 | 1.65 |
| EPS in Rs | 1.43 | 2.64 | -1.42 | -0.20 | -0.90 | 0.18 | 0.82 | 0.69 | 0.71 |
Last Updated: May 31, 2025, 7:13 am
Below is a detailed analysis of the quarterly data for Aashka Hospitals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 10.28 Cr.. The value appears to be declining and may need further review. It has decreased from 12.36 Cr. (Sep 2024) to 10.28 Cr., marking a decrease of 2.08 Cr..
- For Expenses, as of Mar 2025, the value is 10.49 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.89 Cr. (Sep 2024) to 10.49 Cr., marking an increase of 2.60 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 4.47 Cr. (Sep 2024) to -0.21 Cr., marking a decrease of 4.68 Cr..
- For OPM %, as of Mar 2025, the value is -2.04%. The value appears to be declining and may need further review. It has decreased from 36.17% (Sep 2024) to -2.04%, marking a decrease of 38.21%.
- For Other Income, as of Mar 2025, the value is 4.20 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Sep 2024) to 4.20 Cr., marking an increase of 4.13 Cr..
- For Interest, as of Mar 2025, the value is 0.70 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.02 Cr. (Sep 2024) to 0.70 Cr., marking a decrease of 0.32 Cr..
- For Depreciation, as of Mar 2025, the value is 1.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.58 Cr. (Sep 2024) to 1.37 Cr., marking a decrease of 0.21 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.92 Cr.. The value appears to be declining and may need further review. It has decreased from 1.94 Cr. (Sep 2024) to 1.92 Cr., marking a decrease of 0.02 Cr..
- For Tax %, as of Mar 2025, the value is 14.58%. The value appears to be improving (decreasing) as expected. It has decreased from 16.49% (Sep 2024) to 14.58%, marking a decrease of 1.91%.
- For Net Profit, as of Mar 2025, the value is 1.65 Cr.. The value appears strong and on an upward trend. It has increased from 1.62 Cr. (Sep 2024) to 1.65 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.71. The value appears strong and on an upward trend. It has increased from 0.69 (Sep 2024) to 0.71, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:05 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 27.67 | 27.23 | 40.69 | 39.73 | 18.94 | 22.87 | 22.65 |
| Expenses | 18.08 | 18.41 | 30.72 | 31.16 | 18.59 | 18.41 | 18.37 |
| Operating Profit | 9.59 | 8.82 | 9.97 | 8.57 | 0.35 | 4.46 | 4.28 |
| OPM % | 34.66% | 32.39% | 24.50% | 21.57% | 1.85% | 19.50% | 18.90% |
| Other Income | 0.06 | 0.02 | 0.00 | 0.13 | 3.10 | 4.21 | 4.26 |
| Interest | 5.75 | 4.90 | 3.25 | 2.96 | 3.09 | 2.91 | 1.72 |
| Depreciation | 2.54 | 2.56 | 2.61 | 2.90 | 2.93 | 2.92 | 2.95 |
| Profit before tax | 1.36 | 1.38 | 4.11 | 2.84 | -2.57 | 2.84 | 3.87 |
| Tax % | 0.00% | 0.00% | 0.00% | 16.55% | 0.00% | 17.25% | 15.50% |
| Net Profit | 1.36 | 1.38 | 4.11 | 2.37 | -2.57 | 2.36 | 3.27 |
| EPS in Rs | 0.76 | 0.77 | 2.28 | 1.01 | -1.10 | 1.01 | 1.40 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 1.47% | 197.83% | -42.34% | -208.44% | 191.83% | 38.56% |
| Change in YoY Net Profit Growth (%) | 0.00% | 196.36% | -240.16% | -166.10% | 400.27% | -153.27% |
Aashka Hospitals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -4% |
| 3 Years: | -17% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 0% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 25% |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: September 10, 2025, 2:52 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 17.16 | 17.91 | 18.00 | 23.37 | 23.37 | 23.37 | 23.37 |
| Reserves | -1.80 | 6.28 | 11.25 | 73.20 | 70.55 | 72.91 | 76.17 |
| Borrowings | 32.99 | 30.92 | 27.87 | 28.21 | 29.19 | 20.39 | 12.61 |
| Other Liabilities | 5.71 | 4.93 | 7.96 | 4.34 | 4.92 | 4.78 | 3.91 |
| Total Liabilities | 54.06 | 60.04 | 65.08 | 129.12 | 128.03 | 121.45 | 116.06 |
| Fixed Assets | 46.36 | 44.12 | 49.49 | 48.46 | 45.47 | 42.78 | 40.79 |
| CWIP | 0.08 | 0.00 | 0.00 | 0.00 | 0.05 | 0.45 | 0.88 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 7.62 | 15.92 | 15.59 | 80.66 | 82.51 | 78.22 | 74.39 |
| Total Assets | 54.06 | 60.04 | 65.08 | 129.12 | 128.03 | 121.45 | 116.06 |
Below is a detailed analysis of the balance sheet data for Aashka Hospitals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 23.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 23.37 Cr..
- For Reserves, as of Mar 2025, the value is 76.17 Cr.. The value appears strong and on an upward trend. It has increased from 72.91 Cr. (Mar 2024) to 76.17 Cr., marking an increase of 3.26 Cr..
- For Borrowings, as of Mar 2025, the value is 12.61 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 20.39 Cr. (Mar 2024) to 12.61 Cr., marking a decrease of 7.78 Cr..
- For Other Liabilities, as of Mar 2025, the value is 3.91 Cr.. The value appears to be improving (decreasing). It has decreased from 4.78 Cr. (Mar 2024) to 3.91 Cr., marking a decrease of 0.87 Cr..
- For Total Liabilities, as of Mar 2025, the value is 116.06 Cr.. The value appears to be improving (decreasing). It has decreased from 121.45 Cr. (Mar 2024) to 116.06 Cr., marking a decrease of 5.39 Cr..
- For Fixed Assets, as of Mar 2025, the value is 40.79 Cr.. The value appears to be declining and may need further review. It has decreased from 42.78 Cr. (Mar 2024) to 40.79 Cr., marking a decrease of 1.99 Cr..
- For CWIP, as of Mar 2025, the value is 0.88 Cr.. The value appears strong and on an upward trend. It has increased from 0.45 Cr. (Mar 2024) to 0.88 Cr., marking an increase of 0.43 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 74.39 Cr.. The value appears to be declining and may need further review. It has decreased from 78.22 Cr. (Mar 2024) to 74.39 Cr., marking a decrease of 3.83 Cr..
- For Total Assets, as of Mar 2025, the value is 116.06 Cr.. The value appears to be declining and may need further review. It has decreased from 121.45 Cr. (Mar 2024) to 116.06 Cr., marking a decrease of 5.39 Cr..
Notably, the Reserves (76.17 Cr.) exceed the Borrowings (12.61 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -23.40 | -22.10 | -17.90 | -19.64 | -28.84 | -15.93 | -8.33 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 45.64 | 90.48 | 65.66 | 71.84 | 132.20 | 76.93 | 76.06 |
| Inventory Days | 51.35 | 66.55 | 30.28 | 34.97 | 56.59 | 48.75 | 58.63 |
| Days Payable | 296.91 | 247.49 | 241.09 | 101.11 | 365.00 | 263.54 | 130.46 |
| Cash Conversion Cycle | -199.92 | -90.46 | -145.15 | 5.71 | -176.21 | -137.86 | 4.23 |
| Working Capital Days | -93.26 | 19.57 | -38.48 | -34.27 | -126.42 | -123.21 | 3.38 |
| ROCE % | 12.14% | 13.12% | 6.38% | 0.42% | 4.80% | 4.07% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.40 | 1.01 | -1.10 | 1.12 | 2.29 |
| Diluted EPS (Rs.) | 1.40 | 1.01 | -1.10 | 1.12 | 2.29 |
| Cash EPS (Rs.) | 2.66 | 2.26 | 0.15 | 2.25 | 3.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 42.60 | 41.20 | 40.19 | 41.32 | 16.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 42.60 | 41.20 | 40.19 | 41.32 | 16.25 |
| Revenue From Operations / Share (Rs.) | 9.69 | 9.79 | 8.11 | 17.00 | 22.60 |
| PBDIT / Share (Rs.) | 3.26 | 3.71 | 1.44 | 3.59 | 5.51 |
| PBIT / Share (Rs.) | 2.00 | 2.46 | 0.18 | 2.35 | 4.06 |
| PBT / Share (Rs.) | 1.66 | 1.22 | -1.10 | 1.21 | 2.29 |
| Net Profit / Share (Rs.) | 1.40 | 1.01 | -1.10 | 1.01 | 2.29 |
| PBDIT Margin (%) | 33.62 | 37.92 | 17.75 | 21.12 | 24.36 |
| PBIT Margin (%) | 20.61 | 25.17 | 2.27 | 13.82 | 17.96 |
| PBT Margin (%) | 17.08 | 12.44 | -13.56 | 7.14 | 10.11 |
| Net Profit Margin (%) | 14.42 | 10.30 | -13.56 | 5.95 | 10.11 |
| Return on Networth / Equity (%) | 3.28 | 2.44 | -2.73 | 2.44 | 14.06 |
| Return on Capital Employeed (%) | 4.39 | 5.47 | 0.38 | 4.81 | 14.60 |
| Return On Assets (%) | 2.81 | 1.94 | -2.00 | 1.83 | 6.32 |
| Long Term Debt / Equity (X) | 0.06 | 0.08 | 0.16 | 0.17 | 0.68 |
| Total Debt / Equity (X) | 0.12 | 0.21 | 0.31 | 0.29 | 0.74 |
| Asset Turnover Ratio (%) | 0.19 | 0.18 | 0.14 | 0.40 | 0.65 |
| Current Ratio (X) | 1.29 | 0.64 | 0.79 | 0.82 | 1.01 |
| Quick Ratio (X) | 1.25 | 0.62 | 0.77 | 0.78 | 0.97 |
| Inventory Turnover Ratio (X) | 58.72 | 0.00 | 0.00 | 10.54 | 10.90 |
| Interest Coverage Ratio (X) | 4.41 | 2.98 | 1.12 | 3.16 | 3.10 |
| Interest Coverage Ratio (Post Tax) (X) | 2.36 | 1.81 | 0.14 | 1.89 | 2.29 |
| Enterprise Value (Cr.) | 248.61 | 199.58 | 124.69 | 144.22 | 0.00 |
| EV / Net Operating Revenue (X) | 10.98 | 8.73 | 6.58 | 3.63 | 0.00 |
| EV / EBITDA (X) | 32.65 | 23.00 | 37.06 | 17.18 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 10.54 | 7.92 | 5.20 | 2.95 | 0.00 |
| Price / BV (X) | 2.40 | 1.88 | 1.05 | 1.21 | 0.00 |
| Price / Net Operating Revenue (X) | 10.54 | 7.92 | 5.20 | 2.95 | 0.00 |
| EarningsYield | 0.01 | 0.01 | -0.02 | 0.02 | 0.00 |
After reviewing the key financial ratios for Aashka Hospitals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For Diluted EPS (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For Cash EPS (Rs.), as of Mar 24, the value is 2.66. This value is below the healthy minimum of 3. It has increased from 2.26 (Mar 23) to 2.66, marking an increase of 0.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 42.60. It has increased from 41.20 (Mar 23) to 42.60, marking an increase of 1.40.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 42.60. It has increased from 41.20 (Mar 23) to 42.60, marking an increase of 1.40.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 9.69. It has decreased from 9.79 (Mar 23) to 9.69, marking a decrease of 0.10.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 3.26. This value is within the healthy range. It has decreased from 3.71 (Mar 23) to 3.26, marking a decrease of 0.45.
- For PBIT / Share (Rs.), as of Mar 24, the value is 2.00. This value is within the healthy range. It has decreased from 2.46 (Mar 23) to 2.00, marking a decrease of 0.46.
- For PBT / Share (Rs.), as of Mar 24, the value is 1.66. This value is within the healthy range. It has increased from 1.22 (Mar 23) to 1.66, marking an increase of 0.44.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 2. It has increased from 1.01 (Mar 23) to 1.40, marking an increase of 0.39.
- For PBDIT Margin (%), as of Mar 24, the value is 33.62. This value is within the healthy range. It has decreased from 37.92 (Mar 23) to 33.62, marking a decrease of 4.30.
- For PBIT Margin (%), as of Mar 24, the value is 20.61. This value exceeds the healthy maximum of 20. It has decreased from 25.17 (Mar 23) to 20.61, marking a decrease of 4.56.
- For PBT Margin (%), as of Mar 24, the value is 17.08. This value is within the healthy range. It has increased from 12.44 (Mar 23) to 17.08, marking an increase of 4.64.
- For Net Profit Margin (%), as of Mar 24, the value is 14.42. This value exceeds the healthy maximum of 10. It has increased from 10.30 (Mar 23) to 14.42, marking an increase of 4.12.
- For Return on Networth / Equity (%), as of Mar 24, the value is 3.28. This value is below the healthy minimum of 15. It has increased from 2.44 (Mar 23) to 3.28, marking an increase of 0.84.
- For Return on Capital Employeed (%), as of Mar 24, the value is 4.39. This value is below the healthy minimum of 10. It has decreased from 5.47 (Mar 23) to 4.39, marking a decrease of 1.08.
- For Return On Assets (%), as of Mar 24, the value is 2.81. This value is below the healthy minimum of 5. It has increased from 1.94 (Mar 23) to 2.81, marking an increase of 0.87.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.08 (Mar 23) to 0.06, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.12. This value is within the healthy range. It has decreased from 0.21 (Mar 23) to 0.12, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.19. It has increased from 0.18 (Mar 23) to 0.19, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 24, the value is 1.29. This value is below the healthy minimum of 1.5. It has increased from 0.64 (Mar 23) to 1.29, marking an increase of 0.65.
- For Quick Ratio (X), as of Mar 24, the value is 1.25. This value is within the healthy range. It has increased from 0.62 (Mar 23) to 1.25, marking an increase of 0.63.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 58.72. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 23) to 58.72, marking an increase of 58.72.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 4.41. This value is within the healthy range. It has increased from 2.98 (Mar 23) to 4.41, marking an increase of 1.43.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 2.36. This value is below the healthy minimum of 3. It has increased from 1.81 (Mar 23) to 2.36, marking an increase of 0.55.
- For Enterprise Value (Cr.), as of Mar 24, the value is 248.61. It has increased from 199.58 (Mar 23) to 248.61, marking an increase of 49.03.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 10.98. This value exceeds the healthy maximum of 3. It has increased from 8.73 (Mar 23) to 10.98, marking an increase of 2.25.
- For EV / EBITDA (X), as of Mar 24, the value is 32.65. This value exceeds the healthy maximum of 15. It has increased from 23.00 (Mar 23) to 32.65, marking an increase of 9.65.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 10.54. This value exceeds the healthy maximum of 3. It has increased from 7.92 (Mar 23) to 10.54, marking an increase of 2.62.
- For Price / BV (X), as of Mar 24, the value is 2.40. This value is within the healthy range. It has increased from 1.88 (Mar 23) to 2.40, marking an increase of 0.52.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 10.54. This value exceeds the healthy maximum of 3. It has increased from 7.92 (Mar 23) to 10.54, marking an increase of 2.62.
- For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aashka Hospitals Ltd:
- Net Profit Margin: 14.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.39% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.28% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 164 (Industry average Stock P/E: 93.12)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.12
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.42%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Between Sargasan & Reliance Cross Road, Sargasan, Gandhinagar Gujarat 382421 | cs@aashkahospitals.in http://www.aashkahospitals.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bipinchandra D Shah | Chairman & Managing Director |
| Mrs. Shreyarthi B Shah | Director |
| Mr. Umang A Shah | Independent Director |
| Mr. Jigar K Trivedi | Independent Director |
FAQ
What is the intrinsic value of Aashka Hospitals Ltd?
Aashka Hospitals Ltd's intrinsic value (as of 09 December 2025) is 135.93 which is 69.91% higher the current market price of 80.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 187 Cr. market cap, FY2025-2026 high/low of 120/65.1, reserves of ₹76.17 Cr, and liabilities of 116.06 Cr.
What is the Market Cap of Aashka Hospitals Ltd?
The Market Cap of Aashka Hospitals Ltd is 187 Cr..
What is the current Stock Price of Aashka Hospitals Ltd as on 09 December 2025?
The current stock price of Aashka Hospitals Ltd as on 09 December 2025 is 80.0.
What is the High / Low of Aashka Hospitals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aashka Hospitals Ltd stocks is 120/65.1.
What is the Stock P/E of Aashka Hospitals Ltd?
The Stock P/E of Aashka Hospitals Ltd is 164.
What is the Book Value of Aashka Hospitals Ltd?
The Book Value of Aashka Hospitals Ltd is 42.5.
What is the Dividend Yield of Aashka Hospitals Ltd?
The Dividend Yield of Aashka Hospitals Ltd is 0.00 %.
What is the ROCE of Aashka Hospitals Ltd?
The ROCE of Aashka Hospitals Ltd is 4.07 %.
What is the ROE of Aashka Hospitals Ltd?
The ROE of Aashka Hospitals Ltd is 2.39 %.
What is the Face Value of Aashka Hospitals Ltd?
The Face Value of Aashka Hospitals Ltd is 10.0.